MeSH D006391 - hemangioma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009383:Vascular tissue neoplasms
0 Companies
0 Drugs
Success rate
D006391:Â
Hemangioma
D006390:Hemangioendothelioma
0 Companies
0 Drugs
Success rate
D006392:Cavernous hemangioma
0 Companies
0 Drugs
Success rate
D013341:Sturge-weber syndrome
0 Companies
0 Drugs
Success rate
D018324:Capillary hemangioma
0 Companies
0 Drugs
Success rate
D020787:Central nervous system venous angioma
0 Companies
0 Drugs
Success rate
D059885:Kasabach-merritt syndrome
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Laboratoires Pierre Fabre | Propranolol | Hemangiol |  | 2014-04-23 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
100%2/2
Phase 2
70%7/10
Phase 3
77%10/13
Approved: 5Overall Success rate: 54%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use